UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.

The investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in clinical trials compared to Sanofi’s Aubagio as Novartis aims to refresh the Swiss drugmaker’ portfolio of medicines in neurological diseases.

Researchers with the Salk Institute combined two separate analytical techniques to analyze how epigenetics affects certain types of brain cells.

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.

Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

New York-based Neurogene raised $68.5 million in a Series A funding round to support the company’s pipeline of therapeutics aimed at rare neurological diseases.

Shares of Voyager Therapeutics skyrocketed after the company announced a collaborative deal to develop a gene therapy treatment for Parkinson’s disease with Neurocrine Biosciences.

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.